G1945V posted on Stockhouse a good recent history of the share price movement and I replied to his post with some minor edits. The point is that last March/April 2015 were exciting times that saw the share price move from about $1 to $3. During this time period, RVX was very active with China patents announced, Hepalink licensing deal announced, Richmond Club 2015, DM interview on BNN's Business Day, and several articles appearing in the press (links below). What event or combination of events catalyzed this rise in share price?

My main point is that if history repeats itself from last year, then the March/April 2016 period holds a lot of promise for some news that can spark more interest, get more analyst coverage and hopefully affect the share price. Can we see this March/April Spring-catapult of the share price again in 2016? If so, can it be sustained after April 2016 unlike the subsequent decline in the May to August 2015 period after the initial rise to around $3?

If there is a major announcement or movement in share price, maybe it will be next week around the time of Richmond Club 3/23/16. Maybe it will be late April around the time of the Epigenetics: Cancer and Beyond meeting on April 28th, 2016. Maybe neither and I am completely wrong and we'll get no news in March or April. However, in the Q1 2016 webcast, we did hear about another licensing deal to be announced soon. And we do know that there are at least a couple of additional trials that are late in the planning stage that we could potentially hear announced anytime.

Say what you will about Richmond Club, but I would not call the Epigenetics:Cancer and Beyond meeting in April a dog and pony show. This is a legit meeting sponsored by Resverlogix, Constellation Pharmaceuticals, American Society of Clinical Oncology (ASCO) and Nature. Two of the primary organizers are Don McCaffrey and Norman Wong. There are BET bromodomain and epigenetics experts from both academia and industry presenting at this event (including Eric Campeau from Zenith and Ewelina Kulikowski from Resverlogix) with a primary focus on therapeutic potential of pharmacological modulation of the epigenome. There's a good chance that this meeting leads to new analyst coverage, IMO, based upon the presence of George Zavoico from Jones Trading Institutional Services as one of the organizers. Again, I might be completely wrong, but I have a good feeling about hearing something new and significant in late April.

Best regards,

BearDownAZ

P.S.

Here are the links to last year's articles that appeared in late April 2015 (link also available on the RVX events page).

April 27, 2015- BioCentury: Hepalink gains rights to Resverlogix’s RVX-208 in China. Link here: http://www.biocentury.com/dailynews/company/2015-04-27/hepalink-gains-rights-to-resverlogixs-rvx-208-in-china

April 28, 2015- BioWorld Today: Phase III Starting Soon. Resverlogix getting specific: With potential $400M BET, Hepalink licensing accord, by Randy Osborne. Link here to access the full article.

April 28, 2015- Bloomberg Business: Resverlogix in Discussions to Be Bought, by Eric Lam. Link here: http://www.bloomberg.com/news/articles/2015-04-28/resverlogix-ceo-says-company-in-discussions-to-be-bought

April 28, 2015- BioSpace Breaking News: Resverlogix (RVX.TO) CEO Says It’s in Talks With Suitors, After $100M in Q1 Deals, by Riley McDermid. Link here: http://www.biospace.com/News/with-almost-a-100-million-in-deals-for-q1/374186?source=sm&type=twitter_resverlogix042815

April 28, 2015- Fierce Biotech: Resverlogix gets a $116M China Drug development deal, stokes buyout buzz, by John Carroll. Link here: http://www.fiercebiotech.com/story/resverlogix-gets-116m-china-drug-development-deal-stokes-buyout-buzz/2015-04-28

April 28, 2015 - GEN News Highlights: Hepalink Buys China-Area Rights to Resverlogix's CV Candidate for Up-to-$441.5M Link here: http://www.genengnews.com/gen-news-highlights/hepalink-buys-china-area-rights-to-resverlogix-s-cv-candidate-for-up-to-441-5m/81251205/